Tvardi Therapeutics

Tvardi Therapeutics announces new preclinical data further supporting the potential for Tvardi’s STAT3 inhibitors in ulcerative colitis (UC). The full press release can be found here: https://lnkd.in/gAEXVHZm #TvardiTherapeutics #STAT3 #UlcerativeColitis #Biotech

Tvardi Therapeutics is looking forward to participating in three upcoming investor events this September. 📍 Wells Fargo 21st Annual Healthcare Conference – September 9 📍 2026 Cantor Fitzgerald Global Healthcare Conference – September 10 📍 H.C. Wainwright & Co., LLC 28th Annual Global Investment Conference – September 14 Management will meet with investors across all three events, with additional participation in a fireside chat at Cantor and a company presentation at H.C. Wainwright. Learn more in the full press release: https://lnkd.in/gAEXVHZm

Tvardi Therapeutics announced its second quarter 2026 financial results and provided a business update, highlighting continued progress with TTI-109. Key updates include: • Positive topline Phase 1 healthy volunteer results for TTI-109 • Selection of ulcerative colitis (UC) as the initial disease indication for TTI-109 Join us on August 19 at 11:00 AM ET for a KOL webinar featuring Randy Longman, M.D., Ph.D., discussing the clinical potential of TTI-109 in UC. Read the full press release: https://lnkd.in/gAEXVHZm Register for the KOL webinar: https://lnkd.in/gjeGyqGR

Join @Tvardi Therapeutics #TVRD for a KOL webinar on Wednesday, August 19, 2026 at 11am ET featuring Randy Longman, MD, PhD (Weill Cornell Medicine), who will join Tvardi management to discuss the current treatment landscape in ulcerative colitis (UC) and the persistent unmet needs that remain despite recent clinical advances and currently approved therapies. The event will feature new data from Tvardi and a review of the Phase 1 healthy volunteer results supporting the potential of TTI-109 in UC. The discussion will explore the scientific rationale for targeting STAT3, a convergent node implicated in multiple pathways that contribute to the pathogenesis and persistence of UC. Tvardi management will also discuss the planned clinical development strategy for TTI-109. Dr. Longman will provide his perspective on the clinical relevance of the findings and how a STAT3 inhibitor could ultimately fit within the UC treatment paradigm. Register here: https://lnkd.in/gjeGyqGR Read Press Release here: https://bit.ly/4qbfX7l

Today, we announced that we have selected ulcerative colitis as the initial indication for our STAT3 inhibitor, TTI-109. Selection follows completion of the TTI-109 Phase 1 healthy volunteer study, which demonstrated placebo-adjusted reductions across cellular and humoral immune cell subsets implicated in UC pathology. Read press release here: https:// https://lnkd.in/gAEXVHZm

Today we announced our TTI-109 Phase 1 Study which confirms its prodrug design, improved tolerability and pharmacodynamic evidence of STAT3 target engagement 🕗Join our investor webcast today, July 7, at 8:30 a.m. ET. Click here to access the full press release: https://lnkd.in/gAEXVHZm

We are looking forward to participating in the upcoming Jefferies Global Healthcare Conference and the Raymond James BioPharma CEO Strategy Series, including fireside chats with Faisal Khurshid and Ryan Deschner, PhD.

We continue to make significant progress advancing both programs, providing line of sight to two near-term value inflection points: • June 2026: TTI-109 Phase 1 healthy volunteer topline data and clinical development strategy • 2H 2026: TTI-101 Phase 1b/2 HCC topline data

Pleased to partner with Jones Trading as we position Tvardi for continued execution across our clinical programs and upcoming milestones.

Tvardi Therapeutics will host one-on-one investor meetings at the Raymond James Biotech Innovation Symposium in New York City on April 14, 2026. Looking forward to connecting.